» Articles » PMID: 33769500

Long-Term Risk of Ovarian Cancer and Borderline Tumors After Assisted Reproductive Technology

Abstract

Background: Long-term effects of assisted reproductive technology (ART) on ovarian tumor risk are unknown.

Methods: This nationwide cohort study comprises 30 625 women who received ovarian stimulation for ART in 1983-2000 and 9988 subfertile women not treated with ART. Incident invasive and borderline ovarian tumors were ascertained through linkage with the Netherlands Cancer Registry and the Dutch Pathology Registry until July 2018. Ovarian tumor risk in ART-treated women was compared with risks in the general population and the subfertile non-ART group. Statistical tests were 2-sided.

Results: After a median follow-up of 24 years, 158 invasive and 100 borderline ovarian tumors were observed. Ovarian cancer risk in the ART group was increased compared with the general population (standardized incidence ratio [SIR] = 1.43, 95% confidence interval [CI] = 1.18 to 1.71) but not when compared with the non-ART group (age- and parity-adjusted hazard ratio [HR] = 1.02, 95% CI = 0.70 to 1.50). Risk decreased with higher parity and with a larger number of successful ART cycles (resulting in childbirth, Ptrend = .001) but was not associated with the number of unsuccessful ART cycles. Borderline ovarian tumor risk was increased in ART-treated women compared with the general population (SIR = 2.20, 95% CI = 1.66 to 2.86) and with non-ART women (HR = 1.84, 95% CI = 1.08 to 3.14). Risk did not increase with more ART cycles or longer follow-up time.

Conclusions: Increased ovarian cancer risk in ART-treated women compared with the general population is likely explained by nulliparity rather than ART treatment. The increased risk of borderline ovarian tumors after ART must be interpreted with caution because no dose-response relationship was observed.

Citing Articles

Association between ovarian tumors and exposure to assisted reproductive technologies and ovarian stimulation: a systematic review and meta-analysis.

Lobo A, Morbach V, Kelly F, de Moraes F Arch Gynecol Obstet. 2024; 310(6):2753-2765.

PMID: 39412534 DOI: 10.1007/s00404-024-07763-0.


Effects of Infertility Drug Exposure on the Risk of Borderline Ovarian Tumors: A Systematic Review and Meta-Analysis.

Si M, Wang X, Song X, Long X, Qiao J Biomedicines. 2023; 11(7).

PMID: 37509474 PMC: 10376814. DOI: 10.3390/biomedicines11071835.


Ovulation induction drug and ovarian cancer: an updated systematic review and meta-analysis.

Yu L, Sun J, Wang Q, Yu W, Wang A, Zhu S J Ovarian Res. 2023; 16(1):22.

PMID: 36694251 PMC: 9872323. DOI: 10.1186/s13048-022-01084-z.


Risk of ovarian cancer in women who give birth after assisted reproductive technology (ART)-a registry-based Nordic cohort study with follow-up from first pregnancy.

Sandvei M, Pinborg A, Gissler M, Bergh C, Romundstad L, van Leeuwen F Br J Cancer. 2022; 128(5):825-832.

PMID: 36550209 PMC: 9977956. DOI: 10.1038/s41416-022-02097-7.


The challenging management of borderline ovarian tumors (BOTs) in women of childbearing age.

Della Corte L, Mercorio A, Serafino P, Viciglione F, Palumbo M, De Angelis M Front Surg. 2022; 9:973034.

PMID: 36081590 PMC: 9445208. DOI: 10.3389/fsurg.2022.973034.


References
1.
Spaan M, van den Belt-Dusebout A, Schaapveld M, Mooij T, Burger C, van Leeuwen F . Melanoma risk after ovarian stimulation for in vitro fertilization. Hum Reprod. 2015; 30(5):1216-28. DOI: 10.1093/humrep/dev023. View

2.
van den Belt-Dusebout A, Spaan M, Lambalk C, Kortman M, Laven J, van Santbrink E . Ovarian Stimulation for In Vitro Fertilization and Long-term Risk of Breast Cancer. JAMA. 2016; 316(3):300-12. DOI: 10.1001/jama.2016.9389. View

3.
Siristatidis C, Sergentanis T, Kanavidis P, Trivella M, Sotiraki M, Mavromatis I . Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer--a systematic review and meta-analysis. Hum Reprod Update. 2012; 19(2):105-23. DOI: 10.1093/humupd/dms051. View

4.
Lundberg F, Johansson A, Rodriguez-Wallberg K, Gemzell-Danielsson K, Iliadou A . Assisted reproductive technology and risk of ovarian cancer and borderline tumors in parous women: a population-based cohort study. Eur J Epidemiol. 2019; 34(11):1093-1101. PMC: 6861355. DOI: 10.1007/s10654-019-00540-3. View

5.
Reigstad M, Storeng R, Myklebust T, Oldereid N, Omland A, Robsahm T . Cancer Risk in Women Treated with Fertility Drugs According to Parity Status-A Registry-based Cohort Study. Cancer Epidemiol Biomarkers Prev. 2017; 26(6):953-962. PMC: 5457348. DOI: 10.1158/1055-9965.EPI-16-0809. View